Skip to main content
SpringerLink
Log in

Medikamentöse Therapie des metastasierten Nierenzellkarzinoms

  • Chapter
  • First Online:
Book cover Die Urologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 395 Accesses

Zusammenfassung

Das metastasierte Nierenzellkarzinom (mRCC) ist die häufigste metastasierte von Parenchymtumoren der Niere ausgehende Erkrankung und tritt zu 10–20 % nach initial kurativer Behandlung auf. Die weitere Erforschung der Pathomechanismen führte zur Entwicklung zielgerichteter Medikamente wie den Tyrosinkinase-Inhibitoren (TKI) und den Inhibitoren des „mammalian target of rapamycin“ (mTOR) zur Behandlung der fortgeschrittenen metastasierten Erkrankung. Die Substanzen aus der Gruppe der zielgerichteten Therapeutika stehen inzwischen zur Therapie des fortgeschrittenen Nierenzellkarzinoms zur Verfügung und werden in diesem Kapitel dargestellt und diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Escudier B, Pluzanska A, Koralewski P, AVOREN Trial investigators et al (2007a) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111. http://www.ncbi.nlm.nih.gov/pubmed/18156031. Zugegriffen im Oct 2014

    Google Scholar 

  • Escudier B, Eisen T, Stadler WM, Study Group et al (2007b) Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356(2):125–134. http://www.ncbi.nlm.nih.gov/pubmed/17215530

    Google Scholar 

  • Escudier B, Szczylik C, Hutson TE et al (2009) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27(8):1280–1289. http://www.ncbi.nlm.nih.gov/pubmed/19171708

    Google Scholar 

  • Escudier BJ, Porta C, Bono P et al (2012) Abstract and oral presentation at the American Society of Clinical Oncology Annual Congress 2012. J Clin Oncol 30 (Suppl): Abstract CRA4502

    Google Scholar 

  • Gore ME, Griffin CL, Hancock B et al (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375(9715):641–648. http://www.ncbi.nlm.nih.gov/pubmed/20153039

    Google Scholar 

  • Hudes G, Carducci M, Tomczak P, Global ARCC Trial et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. http://www.ncbi.nlm.nih.gov/pubmed/17538086

    Google Scholar 

  • Hutson TE, Escudier B, Esteban E et al (2013) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 32(8):760–767 [Epub vor der Druckversion]. http://www.ncbi.nlm.nih.gov/pubmed/24297950

    Google Scholar 

  • Kramer MW, Steffens S, von Klot C, Merseburger AS, Kuczyk MA (2012) Systemic therapy for metastatic renal cell carcinoma. Aktuelle Urol 43(4):265–268. doi:10.1055/s-0032-1321858, Epub 6 Aug 2012

    Article  CAS  PubMed  Google Scholar 

  • Kruck S, Bedke J, Kuczyk MA, Merseburger AS (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 12(6):777–785

    Article  CAS  PubMed  Google Scholar 

  • Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A, European Association of Urology Guideline Group (2014) EAU guidelines on renal cell carcinoma: the 2014 update. Eur Urol pii: S0302–2838(15)00019–6. doi:10.1016/j.eururo.2015.01.005. [Epub vor der Druckversion]

    Google Scholar 

  • Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353(9146):14–17. http://www.ncbi.nlm.nih.gov/pubmed/10023944

  • Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23(4):832–841

    Article  PubMed  Google Scholar 

  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3):454–463

    Article  PubMed  Google Scholar 

  • Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. http://www.ncbi.nlm.nih.gov/pubmed/17215529

    Google Scholar 

  • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, RECORD-1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, Tomczak P et al (2013a) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552–562. http://www.ncbi.nlm.nih.gov/pubmed/23598172

    Google Scholar 

  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013b) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. doi:10.1056/NEJMoa1303989

    Article  CAS  PubMed  Google Scholar 

  • Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. http://www.ncbi.nlm.nih.gov/pubmed/22056247

    Google Scholar 

  • Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068. doi:10.1200/JCO.2009.23.9764, Epub 25 Jan 2010

    Article  CAS  PubMed  Google Scholar 

  • Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Axel Merseburger, Mohammad Kabbani & Christoph von Klot

Authors
  1. Axel Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Kabbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christoph von Klot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Merseburger .

Editor information

Editors and Affiliations

  1. Universitätsklinikum Mannheim, Klinik für Urologie, Mannheim, Baden-Württemberg, Germany

    Maurice Stephan Michel

  2. Klinik für Urologie, Universitätsklinik Mannheim, Mainz, Germany

    Joachim W. Thüroff

  3. Abt. für Urologie, Universitätsklinikum Salzburg, Salzburg, Austria

    Günther Janetschek

  4. Klinik und Poliklinik für Urologie, Univer Tech Univ Dresden, Dresden, Germany

    Manfred Wirth

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Merseburger, A., Kabbani, M., von Klot, C. (2016). Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. In: Michel, M., Thüroff, J., Janetschek, G., Wirth, M. (eds) Die Urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39940-4_60

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39940-4_60

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39939-8

  • Online ISBN: 978-3-642-39940-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation